We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNOB icon
151
Center Bancorp
CNOB
$1.68B
$313K 0.12%
11,695
-21,195
-64% -$570K
PCVX icon
152
Vaxcyte
PCVX
$8.12B
$309K 0.12%
5,319
-15
-0.3% -$814
REGN icon
153
Regeneron Pharmaceuticals
REGN
$70.9B
$309K 0.12%
400
-2,331
-85% -$1.78M
DXCM icon
154
DexCom
DXCM
$29.6B
$302K 0.11%
4,801
+1,201
+33% +$83.6K
DFTX
155
Definium Therapeutics
DFTX
$5.88B
$300K 0.11%
+15,861
New +$269K
PHAT icon
156
Phathom Pharmaceuticals
PHAT
$873M
$297K 0.11%
26,766
+13,850
+107% +$175K
HUM icon
157
Humana
HUM
$48B
$289K 0.11%
+1,667
New +$342K
ABVX
158
PUT
Abivax
ABVX
$11.9B
$288K 0.11%
+253
New +$29.9K
MDT icon
159
Medtronic
MDT
$106B
$281K 0.1%
3,246
-1,763
-35% -$169K
BBT
160
Beacon Financial Corp
BBT
$2.58B
$281K 0.1%
+9,354
New +$273K
Z icon
161
Zillow
Z
$7.76B
$275K 0.1%
6,657
-4,687
-41% -$249K
EPRX
162
Eupraxia Pharmaceuticals
EPRX
$431M
$275K 0.1%
+37,926
New +$305K
SABS icon
163
SAB Biotherapeutics
SABS
$271M
$267K 0.1%
69,732
+49,942
+252% +$199K
BIOA
164
BioAge Labs
BIOA
$1.01B
$265K 0.1%
15,167
-57,607
-79% -$1.11M
MAZE
165
Maze Therapeutics
MAZE
$1.56B
$262K 0.1%
8,768
+2,163
+33% +$95.5K
PSIX
166
Power Solutions International
PSIX
$697M
$261K 0.1%
+4,295
New +$306K
ELVN icon
167
Enliven Therapeutics
ELVN
$3.8B
$259K 0.1%
+6,606
New +$183K
YMM icon
168
Full Truck Alliance
YMM
$9.48B
$256K 0.1%
+30,811
New +$293K
AYTU icon
169
AYTU BioPharma
AYTU
$23.1M
$254K 0.09%
92,897
+13,482
+17% +$34.5K
SE icon
170
Sea Limited
SE
$63.7B
$248K 0.09%
3,000
-2,000
-40% -$214K
RPRX icon
171
Royalty Pharma
RPRX
$25.8B
$248K 0.09%
5,178
-1,416
-21% -$62K
INO icon
172
Inovio Pharmaceuticals
INO
$92.1M
$247K 0.09%
142,164
– –
TMO icon
173
Thermo Fisher Scientific
TMO
$198B
$247K 0.09%
503
+43
+9% +$23.3K
ANNX icon
174
CALL
Annexon
ANNX
$950M
$245K 0.09%
897
+69
+8% +$388
AZN icon
175
AstraZeneca
AZN
$262B
$244K 0.09%
+1,236
New +$238K
5 6
7
8 9

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.